| Fiscal period | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 |
|---|
| Net Sales | 43,075.00 | 34,608.00 | 31,904.00 | 30,578.00 | 27,390.00 | 20,853.00 | 20,405.00 | 20,247.00 | 19,657.00 | 19,050.00 |
| Total Revenues | 43,075.00 | 34,608.00 | 31,904.00 | 30,578.00 | 27,390.00 | 20,853.00 | 20,405.00 | 20,247.00 | 19,657.00 | 19,050.00 |
| Cost of Products Sold | 18,537.00 | 15,003.00 | 13,231.00 | 12,706.00 | 12,409.00 | 9,094.00 | 8,747.00 | 9,218.00 | 9,193.00 | 8,899.00 |
| Amortization of intangible assets | 2,047.00 | 2,132.00 | 1,936.00 | 2,178.00 | 1,975.00 | 550.00 | 601.00 | 555.00 | 588.00 | 595.00 |
| Research and development | 2,742.00 | 2,420.00 | 2,440.00 | 2,300.00 | 2,260.00 | 1,447.00 | 1,405.00 | 1,345.00 | 1,371.00 | 1,461.00 |
| Acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative | 11,324.00 | 9,696.00 | 9,765.00 | 9,744.00 | 9,182.00 | 6,736.00 | 6,785.00 | 6,530.00 | 6,372.00 | 6,735.00 |
| Gain on sale of business | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Cost and Expenses | 34,650.00 | 29,251.00 | 27,372.00 | 26,928.00 | 25,826.00 | 17,827.00 | 17,538.00 | 17,648.00 | 17,524.00 | 17,690.00 |
| Operating earnings | 8,425.00 | 5,357.00 | 4,532.00 | 3,650.00 | 1,564.00 | 3,026.00 | 2,867.00 | 2,599.00 | 2,133.00 | 1,360.00 |
| Interest expense | 533.00 | 546.00 | 670.00 | 826.00 | 904.00 | 431.00 | 163.00 | 150.00 | 145.00 | 320.00 |
| Interest income | 43.00 | 46.00 | 94.00 | 105.00 | 124.00 | 99.00 | 105.00 | 77.00 | 67.00 | 59.00 |
| Other income (expense), net | 277.00 | 103.00 | 191.00 | 139.00 | 1,413.00 | (786.00) | 281.00 | (14.00) | 32.00 | 1.00 |
| Net foreign exchange gain (loss) | (1.00) | 8.00 | (7.00) | (28.00) | 34.00 | (495.00) | 93.00 | 24.00 | (46.00) | 31.00 |
| Income (Loss) from TAP Pharmaceutical Products Inc. joint venture | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain (loss) on extinguishment of debt | -- | -- | (63.00) | (167.00) | -- | -- | -- | (18.00) | 0.00 | (1,351.00) |
| Earnings before taxes | 8,211.00 | 4,968.00 | 4,077.00 | 2,873.00 | 2,231.00 | 1,413.00 | 3,183.00 | 2,518.00 | 2,041.00 | (220.00) |
| Current:U.S. Federal and Possessions | 859.00 | 39.00 | 291.00 | (812.00) | 2,260.00 | 71.00 | 64.00 | 27.00 | 4.00 | (44.00) |
| Current-State | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Current- Foreign | 790.00 | 566.00 | 590.00 | 606.00 | 508.00 | 406.00 | 220.00 | 468.00 | 482.00 | 819.00 |
| Deferred:Domestic | (355.00) | (18.00) | (305.00) | 832.00 | (679.00) | (147.00) | 313.00 | 298.00 | (308.00) | (572.00) |
| Deferred- Foreign | (154.00) | (90.00) | (186.00) | (87.00) | (211.00) | 20.00 | (20.00) | 4.00 | (125.00) | (660.00) |
| Deferred:Enacted tax rate changes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Taxes on earnings | 1,140.00 | 497.00 | 390.00 | 539.00 | 1,878.00 | 350.00 | 577.00 | 797.00 | 53.00 | (457.00) |
| Income (loss) from Continuing Operations | 7,071.00 | 4,471.00 | 3,687.00 | 2,334.00 | 353.00 | 1,063.00 | 2,606.00 | 1,721.00 | 1,988.00 | 237.00 |
| Earnings (Loss) from Discontinued Operations, net of taxes | -- | 24.00 | -- | 34.00 | 124.00 | 321.00 | 65.00 | 563.00 | 588.00 | 5,726.00 |
| Gain on sale of discontinued operations, net of tax | -- | -- | -- | -- | -- | 16.00 | 1,752.00 | 0.00 | -- | -- |
| Net earnings allocable to Common Units | 7,071.00 | 4,495.00 | 3,687.00 | 2,368.00 | 477.00 | 1,400.00 | 4,423.00 | 2,284.00 | 2,576.00 | 5,963.00 |
| Earnings Per Share (Basic) - Cont Ops | 3.97 | 2.51 | 2.07 | 1.32 | 0.20 | 0.71 | 1.73 | 1.13 | 1.27 | 0.15 |
| EPS (Basic) : Disc Ops | -- | 0.01 | -- | 0.02 | 0.07 | 0.23 | 1.21 | 0.37 | 0.37 | 3.61 |
| Basic earnings per common share | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.76 |
| Earnings Per Share (Diluted) - Cont Ops | 3.94 | 2.49 | 2.06 | 1.31 | 0.20 | -- | 1.72 | 1.12 | 1.26 | 0.15 |
| Earnings Per Share (Diluted) - Disc Ops | -- | 0.01 | -- | 0.02 | 0.07 | 0.23 | 1.20 | 0.37 | 0.36 | 3.57 |
| Diluted earnings per common share | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 | 1.49 | 1.62 | 3.72 |
| Average Number of Common Shares Outstanding (Basic) | 1,775.00 | 1,773.00 | 1,768.00 | 1,758.00 | 1,740.00 | 1,477.00 | 1,496.00 | 1,516.00 | 1,558.00 | 1,575.00 |
| Average Number of Common Shares Outstanding (Diluted) | 1,789.00 | 1,786.00 | 1,781.00 | 1,770.00 | 1,749.00 | 1,483.00 | 1,506.00 | 1,527.00 | 1,574.00 | 1,592.00 |